PL371773A1 - Zmodyfikowana ludzka limfopoetyna z grasiczej tkanki śródmiąższowej - Google Patents

Zmodyfikowana ludzka limfopoetyna z grasiczej tkanki śródmiąższowej

Info

Publication number
PL371773A1
PL371773A1 PL02371773A PL37177302A PL371773A1 PL 371773 A1 PL371773 A1 PL 371773A1 PL 02371773 A PL02371773 A PL 02371773A PL 37177302 A PL37177302 A PL 37177302A PL 371773 A1 PL371773 A1 PL 371773A1
Authority
PL
Poland
Prior art keywords
modified human
thymic stromal
stromal lymphopoietin
human thymic
lymphopoietin
Prior art date
Application number
PL02371773A
Other languages
English (en)
Inventor
Stewart D. Lyman
Ness Kirk P. van
Raymond J. Paxton
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of PL371773A1 publication Critical patent/PL371773A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL02371773A 2001-07-23 2002-07-23 Zmodyfikowana ludzka limfopoetyna z grasiczej tkanki śródmiąższowej PL371773A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30734501P 2001-07-23 2001-07-23

Publications (1)

Publication Number Publication Date
PL371773A1 true PL371773A1 (pl) 2005-06-27

Family

ID=23189325

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371773A PL371773A1 (pl) 2001-07-23 2002-07-23 Zmodyfikowana ludzka limfopoetyna z grasiczej tkanki śródmiąższowej

Country Status (11)

Country Link
US (9) US7288633B2 (pl)
EP (1) EP1417231B1 (pl)
JP (2) JP5329016B2 (pl)
AU (1) AU2002359238B2 (pl)
CA (1) CA2454578C (pl)
DK (1) DK1417231T3 (pl)
ES (1) ES2422879T3 (pl)
MX (1) MXPA04000631A (pl)
PL (1) PL371773A1 (pl)
PT (1) PT1417231E (pl)
WO (1) WO2003032898A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5329016B2 (ja) * 2001-07-23 2013-10-30 イミュネックス・コーポレーション 修飾したヒト胸腺ストローマ細胞リンホポエチン
ES2384960T3 (es) * 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
ES2313076T3 (es) * 2003-07-18 2009-03-01 Schering Corporation Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica.
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA2698357C (en) * 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
CA2779384C (en) 2009-11-04 2018-02-27 Schering Corporation Engineered anti-tslp antibody
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
US11001624B2 (en) 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
AU672606B2 (en) 1992-04-30 1996-10-10 Amgen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
GB9209874D0 (en) 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
JP2002506625A (ja) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド サイトカインレセプター共通γ鎖様
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU6246199A (en) 1998-09-21 2000-04-10 Schering Corporation Human interleukin-b50, therapeutic uses
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
WO2000039149A2 (en) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
MXPA02012747A (es) 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
JP5329016B2 (ja) 2001-07-23 2013-10-30 イミュネックス・コーポレーション 修飾したヒト胸腺ストローマ細胞リンホポエチン
GB2381685A (en) 2001-10-30 2003-05-07 Amino Holdings Ltd Gateway device for converting digital signals to analogue signals
PT2311869E (pt) * 2002-02-01 2013-03-04 Merck Sharp & Dohme Utilização de reagentes relacionados com citoquinas de mamíferos
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
ES2313076T3 (es) 2003-07-18 2009-03-01 Schering Corporation Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica.
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
AU2005277236A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
EP1981912A2 (en) 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
AU2008265128A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases

Also Published As

Publication number Publication date
US7709217B2 (en) 2010-05-04
CA2454578A1 (en) 2003-04-24
CA2454578C (en) 2013-06-25
WO2003032898A3 (en) 2003-08-14
EP1417231A2 (en) 2004-05-12
US7288633B2 (en) 2007-10-30
US20160377630A1 (en) 2016-12-29
JP5329016B2 (ja) 2013-10-30
US20130023647A1 (en) 2013-01-24
US9045558B2 (en) 2015-06-02
US20210102955A1 (en) 2021-04-08
JP2010279365A (ja) 2010-12-16
MXPA04000631A (es) 2004-06-25
US20110230637A1 (en) 2011-09-22
AU2002359238B2 (en) 2008-01-17
EP1417231B1 (en) 2013-06-19
ES2422879T3 (es) 2013-09-16
US20070218523A1 (en) 2007-09-20
US8598318B2 (en) 2013-12-03
JP2005505293A (ja) 2005-02-24
US20100167393A1 (en) 2010-07-01
US20150252089A1 (en) 2015-09-10
US20080145866A1 (en) 2008-06-19
EP1417231A4 (en) 2004-12-15
DK1417231T3 (da) 2013-07-22
WO2003032898A2 (en) 2003-04-24
PT1417231E (pt) 2013-07-29
US7973151B2 (en) 2011-07-05
US20140093956A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
IL200768A0 (en) Hematopietic cells from human embryonic stem cells
GB0201149D0 (en) Prosthesis
GB0219280D0 (en) Prosthesis
EP1546112A4 (en) IMIDAZOLOPYRIDINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB0124847D0 (en) Prosthesis
EP1417231A4 (en) MODIFIED HUMAN THOMATIC STROMAL THYMIC LYMPHOPOIETINE (TSLP)
EP1637589A4 (en) NEW STEM CELL DERIVED FROM ADULT FABRIC AND THEIR USE
AU2003296369A8 (en) Imminoamines and preparation thereof
AU2003226899A8 (en) Human diabetes-mediating proteins
GB0301009D0 (en) Laryngoscopes and parts thereof
GB2410041B (en) Canopy
AU2003252075A8 (en) Human immunosuppressive protein
GB0200929D0 (en) Tissue rejection
AU2003270876A8 (en) Anti-hla assay and methods
HUP0202901A2 (hu) Módosított metatézis-katalizátorok
GB2389046B (en) Spinal prosthesis
GB0107282D0 (en) Acromial prosthesis
TW564743U (en) Multifunctional chair
TW475384U (en) Multifunctional chair
CA91654S (en) Chair
CA94218S (en) Chair
CA91530S (en) Chair
CA91652S (en) Chair
TW418874U (en) Modified quick-undo canopy
HU0102381D0 (en) Procedure of converting the single-duct collecting chimney for individual units

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)